Antiepileptic Drugs in Patients With Aggression and Epilepsy by Dadgari, Bahare
REVIEW ARTICLE
Antiepileptic Drugs in Patients with Aggression and Epilepsy
Bahare Dadgari*
Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Corresponding Author: Bahare Dadgari, Imam Ali Blvd, Rafsanjan, Kerman Province, Iran. Phone: +989153142682,  
E-mail: Bahare.dadgari@gmail.com
ABSTRACT
In the United States, the prevalence and incidence of epilepsy are about 5 to 8.4 per 1000 and 
35.5 to 71 per 100,000 persons per year, respectively. Epilepsy management is a personalized 
and multifactorial medical approach; it is based on the type of epilepsy syndrome, severity and 
frequency of epileptic seizures, antiepileptic drug’s (AED) side effects, drug-drug interactions, 
disease-related psychosocial problems, and the overall lifestyle of the patient. Aggressive 
behavior is a major side effect of many AEDs. It deteriorates patients’ health. In this study, we 
reviewed different mechanisms of aggression in patients with or without epilepsy, and eventually, 
we introduced medications that potentially managed both.
INTRODUCTION
According to the Institute of Medicine, the incidence and 
prevalence of epilepsy in the United States are 35.5 to 71 
per 100,000 and 5 to 8.4 per 1000 persons per year or ap-
proximately 1% of the population, respectively (1). Over 
the past 20 years, more than 15 different antiepileptic drugs 
(AEDs) with more unique characteristics and mechanism of 
action have been introduced in the US drug market.2 Despite 
the availability of new medications, more than 30% of the 
patients are refractory to treatment. This demands for new 
strategies so that the medical requirements for managing ep-
ilepsy can be fulfilled. Epilepsy management is an individu-
alized and multifactorial medical approach.
Traditionally, seizures are classified into (2) main cate-
gories: focal (partial) and generalized. Although the initia-
tion of AEDs is not often required in individuals with a sin-
gle reversible provoked seizure, it is required in individuals 
who are at the risk of recurrent seizures. Different factors 
considered for the initiation of AEDs in individuals with ep-
ilepsy are as follows: type of epilepsy, patients’ comorbid 
medical conditions, concomitant medications, side effects 
of AEDs, patients’ lifestyle, their psychosocioeconom-
ic conditions, and their gender.(3) Long-term video-EEG 
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monitoring (LTM) is used to diagnose the type of epilepsy 
syndrome.(4)
Epilepsy has been frequently associated with aggressive 
behavior. Baseline pathology, side effects of AEDs, or pre-
ictal, ictal, and postictal states may be one of the reasons 
for such aggressive behavior. The prevalence of psychoses 
in epilepsy is in the range of 2% to 7%. Both epilepsy itself 
and the AEDs are contributing factors for the aggressive be-
havior in patients with epilepsy. Here, we review different 
studies describing the underlying mechanism of aggression, 
epilepsy, and the common pathophysiology of their coexis-
tence. In addition, we review different AEDs with potential 
effectiveness on both epilepsy and aggression.(5)
NEUROBIOLOGY MECHANISMS COMMON TO 
AGGRESSION AND EPILEPSY
Studies on aggression have shown different underlying 
mechanisms of aggression because of dysregulation in neu-
rotransmitters and structural changes in the brain, leading to 
a seizure. To address both issues-neurotransmitter dysregu-
lation and brain’s structural changes-AEDs are prescribed as 
a common treatment method.
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Studies on violent and aggressive behavior have revealed 
that the reduction of the orbitofrontal cortex gray matter (dorsal 
and ventral prefrontal cortices), the amygdala, hippocampus, 
anterior cingulate, hypothalamus, frontal lobes, limbic system, 
and thalamus may be the underlying factors behind some ag-
gressive behaviors.(6) On the other hand, epileptic seizures can 
cause changes in subcortical structures such as the thalamus 
and brain stem, leading to ictal behavioral manifestation.(7)
Studies have hypothesized that impulsive behavior and 
aggression are suppressed by signals originating in the pre-
frontal cortex (PFC), which inhibit other areas of the brain 
involved in the aggressive behavior such as the amygdala, 
anterior cingulate, thalamus, and hypothalamus. Any struc-
tural changes or damages to PFC lead to the downregula-
tion of the inhibitory effect of PFC and firing of thalamus 
and hypothalamus, which eventually trigger the adrenal 
response (Figure 1).
AEDs lead to the dysregulation of neurotransmitters 
leading to epilepsy and aggression. Monoamines and other 
neuroactive compounds are targeted by AEDs, thereby in-
fluencing the initiation of seizure. Some of them have been 
listed below:
Serotonin
Serotonin modulates the orbital frontal cortex and anterior 
cingulate cortex by affecting 5-HT2 receptors in these regions, 
leading to the suppression of impulsive aggression.(8) There 
are 2 different serotonin receptor subtypes that have shown 
different mechanisms of action. Antagonists of the 5-HT2A 
receptors reduce aggression as opposed to the agonists of the 
5-HT2C receptors that reduce aggression.(9) Studies have 
shown that selective serotonin reuptake inhibitors have both 
antiaggressive and anticonvulsant effects on animal models 
of epilepsy.(10) Agonists of the 5-HT1A receptors are an-
ticonvulsant, whereas the antagonists of 5-HT2C receptors 
cause rare fatal epilepsy in mice. Agonists of the 5-HT1A/1B 
receptors demonstrate antiaggressive effect.(11-13)
Dopamine
Dopamine plays a significant role in epileptogenesis and 
aggression, depending on the types of receptors that are 
involved. The nonselective D1/D2 agonists have anticon-
vulsant properties, whereas D1/D2 antagonists have a pro-
convulsant effect. Also, dopamine is a part of the initiation 
circuit of aggression.(1-164)
Noradrenaline
Noradrenaline (NA) is an antiepileptic neurotransmitter that 
works through alpha-1 (α1)- and alpha-2 (α2)-adrenoceptors. 
The α2-adrenoreceptor antagonists provoke epilepsy, where-
as their agonists suppress it. The increased or decreased level 
of NA is associated with aggression. Clonidine works as an 
α2-adrenoceptor agonist that decreases NA neuronal activity 
and decreases aggression.(17)
Gamma-Aminobutyric Acid
There are no clear data supporting whether or not the gam-
ma-aminobutyric acid (GABA) level is decreased or in-
creased in aggression, and whether enhancing GABA is 
anti- or proaggressive. In addition, GABA receptors play an 
inhibitory role in epilepsy; however, it can vary between dif-
ferent types of epilepsy syndromes.
Glutamate
Glutamate works through its excitatory N-methyl-D-as-
partate receptor (NMDA) and α-amino-3-hydroxy-5-meth-
yl-4-isoxazolepropionic acid receptor (AMPA) receptors. 
The expression of glutamate (NMDA, AMPA, and kainite 
receptors) leads to epileptogenesis. The NMDA antagonists 
have shown proconvulsant action at very high doses and 
anticonvulsant properties at low doses, whereas AMPA an-
tagonists have anticonvulsant activity. Animal models have 
shown the dose-dependent effect of NMDA antagonists on 
aggression as they act as proaggression agents at a low dose 
and as antiaggression agents at a high dose.(18-21)
TARGETED DRUGS
There are debates regarding what would be the best option 
to target both epilepsy and aggression in patients. Based on 
the available evidence, we can say that some AEDs seem 
to be associated with a higher risk of aggression than oth-
ers, including clobazam (8%), clonazepam (no report), le-
vetiracetam (1%-10%), perampanel (1%-10%), phenobar-
bital, tiagabine (2%-5%), topiramate (1%-10%), vigabatrin 
(1%-10%), lacosamide (1%-10%), and zonisamide (>10%). 
Many AEDs such as valproic acid (1%-10%), topiramate 
(1%-10%), gabapentin (1%-10%), lamotrigine, carbamaz-
epine, oxcarbazepine, lamotrigine, and maybe pregabalin 
(0.1%-1%), and phenytoin (no reported aggression) are also 
used to treat aggression. Before listing the different AEDs 
and their anti- or proaggressive actions, we should mention 
about 3 phenomena that are involved with this combination. 
They are as follows:
1. Enhancing GABA with paradoxical proaggressive effect: 
The GABA system with both inhibitory and excitatory 
effects can be imbalanced in epilepsy. Although GABA 
displays antiaggressive actions, in some regions of the 
epileptic brain, it can act as a proaggressive agent.(22)
2. Dose-dependent opposite effect of NMDA receptor an-
tagonists: This effect is dose dependent and related to 
the region where epilepsy occurs in the brain.(23)
3. Forced normalization: The relationship between aggres-
sion and epilepsy has been observed over many years. 
There is a hypothesis that the better the seizures are con-
trolled, the worse psychiatric status of the patient will 
be. Although this observation and hypothesis have not 
been well explained and well studied, different aspects 
of this correlation have been considered. Is worsening of 
the psychiatric symptoms because of the side effect of 
AEDs? Is it a pathophysiologic progression of the dis-
ease? Or is it really a result of seizure suppression?(24)
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Valproic Acid
Valproate (VPA) blocks the voltage-dependent sodium 
channel and inhibits the cytochrome P450 (CYP) system 
and uridine diphosphate-glucuronyltransferase (UGT)-glu-
curonidation. VPA-related hyperammonemic encephalopa-
thy (VHE) causes lethargy and increased seizures. VPA has 
some inhibitory effects on the NMDA and AMPA receptors 
that can decrease aggression. In different trials, VPA has re-
ported aggression with the incidence of 1% to 10%, but it is 
also considered as a mood stabilizer.
Topiramate
Topiramate blocks the voltage-dependent sodium channel, 
enhances the activity of GABA at a nonbenzodiazepine site 
on GABA(A) receptors, and antagonizes an NMDA-gluta-
mate receptor. It also weakly inhibits carbonic anhydrase in 
the central nervous system.25,26 Impaired cognition and ex-
pressive language are the side effects of topiramate. This re-
sults in aggression, which is as common as 1% to 10% of the 
patients using this drug, with the aggression tendency being 
more in children than in adults. Topiramate has not yet been 
proven as an antiaggression agent, and the use of this drug as 
an antiaggression agent is very controversial.
Lamotrigine
Lamotrigine blocks the repetitive firing of neurons by inacti-
vating voltage-dependent sodium channels and diminishes the 
release of these excitatory neurotransmitters. It is used in the 
adjunctive treatment of focal seizures in adults and children as 
young as 2 years old, as well as for adjunctive therapy for pri-
mary generalized tonic-clonic seizures and Lennox-Gastaut 
syndrome.26 The level of drugs increases when they interact 
with VPA. Even though there are reports of aggressive behav-
ior (1%-10%) because of the side effect, this medicine is con-
sidered as a mood stabilizer and an antiaggressive.
Carbamazepine
Carbamazepine can be used to treat focal and general-
ized seizures. It binds to voltage-dependent sodium chan-
nels, which leads to the inhibition of action potential. It is 
a CYP 450 inducer. It can cause fluid retention (SIADH) 
and Stevens-Johnson syndrome mostly in Asian with the 
HLA-B*1502 allele. Carbamazepine has autoinduction 
during the first 2-3 months and therefore levels should be 
monitored frequently due to the autoinduction. And if needed 
the dosage should be increased until achieving more stable 
level and dosage after the period of autoinduction. Carba-
mazepine acts as an antiaggressive agent with a very low 
incidence of aggression as a side effect (0.01%-0.1%).
Oxcarbazepine
Oxcarbazepine is used as first-line treatment for focal and 
secondarily generalized tonic-clonic seizures. It also mini-
mally affects the CYP system. It has antiaggressive effects 
and a very low rate of aggression (1-2%) as a side effect.
Phenytoin
It is used for focal and generalized seizures, status epilep-
ticus, and as a second-line agent for patients with mixed 
seizures. It blocks voltage-dependent sodium channels and 
inhibits calcium-calmodulin protein phosphorylation. Phe-
nytoin is an inducer of CYP and UGT-glucuronidation. Phe-
nytoin can cause a small decrease in irritability.
Eslicarbazepine
Its mechanism of action is similar to that of carbamazepine 
and oxcarbazepine; it blocks voltage-gated sodium channels 
and is an inducer of CYP3A4 and uridine diphosphate-glu-
curonosyltransferase (UGT) 1A1 and a moderate inhibitor 
of CYP2C19. It can be used in epilepsy and aggression, with 
a very uncommon incidence of aggression as a side effect 
(0.1%-1%).
CONCLUSION
Since aggression is the side effect of many AEDs, treat-
ment of epilepsy can be very challenging in patients with 
cognitive and behavioral comorbidities. Levetiracetam, per-
ampanel, gabapentin, topiramate, zonisamide, and pheno-
barbital have the highest incidence rate of aggression in the 
profile and should be avoided in patients with this morbidity. 
Dosing should be very slow and gradual. Furthermore, there 
are AEDs that can be considered as better options in patients 
with epilepsy and aggression such as oxcarbazepine, carba-
mazepine, eslicarbazepine, lamotrigine, and valproic acid.
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